Home LiteratureArticle Details
PMID: 15994776 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, P.H.S.

A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates.

Journal of virology ·Vol. 79 ·No. 14 ·2005-07-00 ·Pages 8828-34

Barouch DH, Yang ZY, Kong WP, Korioth-Schmitz B, Sumida SM, Truitt DM, Kishko MG, Arthur JC, Miura A, Mascola JR, Letvin NL, Nabel GJ

Abstract

Plasmid DNA vaccines elicit potent and protective immune responses in numerous small-animal models of infectious diseases. However, their immunogenicity in primates appears less potent. Here we investigate a novel approach that optimizes regulatory elements in the plasmid backbone to improve the immunogenicity of DNA vaccines. Among various regions analyzed, we found that the addition of a regulatory sequence from the R region of the long terminal repeat from human T-cell leukemia virus type 1 (HTLV-1) to the cytomegalovirus (CMV) enhancer/promoter increased transgene expression 5- to 10-fold and improved cellular immune responses to human immunodeficiency virus type 1 (HIV-1) antigens. In cynomolgus monkeys, DNA vaccines containing the CMV enhancer/promoter with the HTLV-1 R region (CMV/R) induced markedly higher cellular immune responses to HIV-1 Env from clades A, B, and C and to HIV-1 Gag-Pol-Nef compared with the parental DNA vaccines. These data demonstrate that optimization of specific regulatory elements can substantially improve the immunogenicity of DNA vaccines encoding multiple antigens in small animals and in nonhuman primates. This strategy could therefore be explored as a potential method to enhance DNA vaccine immunogenicity in humans.

MeSH Terms
3T3 Cells AIDS Vaccines/immunology Animals Genes, Regulator/physiology HIV-1/immunology Human T-lymphotropic virus 1/genetics Immunization Interferon-gamma/biosynthesis Macaca fascicularis Mice Mice, Inbred BALB C Plasmids Terminal Repeat Sequences Vaccines, DNA/immunology Virus Replication
Chemicals
AIDS Vaccines Vaccines, DNA Interferon-gamma
Authors & Affiliations
12 authors, click to expand affiliations / ORCID
Barouch Dan H
Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA.
Yang Zhi-yong
Kong Wing-pui
Korioth-Schmitz Birgit
Sumida Shawn M
Truitt Diana M
Kishko Michael G
Arthur Janelle C
Miura Ayako
Mascola John R
Letvin Norman L
Nabel Gary J
References (40)
40 references, click to expand
  1. Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines.
    Immunity. 1995 Feb;2(2):129-35 PMID: 7895169
  2. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients.
    Lancet. 1998 May 2;351(9112):1320-5 PMID: 9643795
  3. Sequence requirements of ATF2 and CREB binding to the human T-cell leukemia virus type 1 LTR R region.
    Virology. 1996 Apr 15;218(2):362-71 PMID: 8610463
  4. The RU5 ('R') region from human leukaemia viruses (HTLV-1) contains an internal ribosome entry site (IRES)-like sequence.
    FEBS Lett. 1996 Sep 2;392(3):220-4 PMID: 8774848
  5. DNA vaccines.
    Annu Rev Immunol. 1997;15:617-48 PMID: 9143702
  6. Development of improved vectors for DNA-based immunization and other gene therapy applications.
    Vaccine. 1997 Jun;15(8):801-3 PMID: 9234518
  7. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection.
    N Engl J Med. 1997 Oct 30;337(18):1267-74 PMID: 9345075
  8. Immunization for Ebola virus infection.
    Nat Med. 1998 Jan;4(1):37-42 PMID: 9427604
  9. Modulation of amplitude and direction of in vivo immune responses by co-administration of cytokine gene expression cassettes with DNA immunogens.
    Eur J Immunol. 1998 Mar;28(3):1089-103 PMID: 9541605
  10. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response.
    J Infect Dis. 1998 Jul;178(1):92-100 PMID: 9652427
  11. Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/Ig administration.
    J Immunol. 1998 Aug 15;161(4):1875-82 PMID: 9712056
  12. A plasmid encoding murine granulocyte-macrophage colony-stimulating factor increases protection conferred by a malaria DNA vaccine.
    J Immunol. 1998 Sep 1;161(5):2325-32 PMID: 9725227
  13. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine.
    Science. 1998 Oct 16;282(5388):476-80 PMID: 9774275
  14. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes.
    Science. 1999 Feb 5;283(5403):857-60 PMID: 9933172
  15. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques.
    J Exp Med. 1999 Mar 15;189(6):991-8 PMID: 10075982
  16. Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV.
    J Virol. 2000 Mar;74(6):2740-51 PMID: 10684290
  17. Modulation of antigen-specific humoral responses in rhesus macaques by using cytokine cDNAs as DNA vaccine adjuvants.
    J Virol. 2000 Apr;74(7):3427-9 PMID: 10708463
  18. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo.
    J Immunol. 2000 May 1;164(9):4635-40 PMID: 10779767
  19. Simian immunodeficiency virus (SIV) gag DNA-vaccinated rhesus monkeys develop secondary cytotoxic T-lymphocyte responses and control viral replication after pathogenic SIV infection.
    J Virol. 2000 Aug;74(16):7485-95 PMID: 10906202
  20. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination.
    Science. 2000 Oct 20;290(5491):486-92 PMID: 11039923
  21. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.
    Science. 2001 Apr 6;292(5514):69-74 PMID: 11393868
  22. Human immunodeficiency virus type 1-specific immunity after genetic immunization is enhanced by modification of Gag and Pol expression.
    J Virol. 2001 May;75(10):4947-51 PMID: 11312370
  23. Safety of a GM-CSF adjuvant-plasmid DNA malaria vaccine.
    Gene Ther. 2001 Jul;8(13):1011-23 PMID: 11438836
  24. High and sustained transgene expression in vivo from plasmid vectors containing a hybrid ubiquitin promoter.
    Mol Ther. 2001 Jul;4(1):75-82 PMID: 11472109
  25. Effects of antigen and genetic adjuvants on immune responses to human immunodeficiency virus DNA vaccines in mice.
    J Virol. 2002 Jan;76(1):243-50 PMID: 11739689
  26. Potent CD4+ T cell responses elicited by a bicistronic HIV-1 DNA vaccine expressing gp120 and GM-CSF.
    J Immunol. 2002 Jan 15;168(2):562-8 PMID: 11777947
  27. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.
    Nature. 2002 Jan 17;415(6869):331-5 PMID: 11797011
  28. Prospects for vaccine protection against HIV-1 infection and AIDS.
    Annu Rev Immunol. 2002;20:73-99 PMID: 11861598
  29. Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization.
    J Virol. 2002 Jun;76(11):5357-68 PMID: 11991964
  30. Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines.
    J Virol. 2003 Aug;77(16):8729-35 PMID: 12885892
  31. Immunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNA vaccines.
    J Virol. 2003 Dec;77(23):12764-72 PMID: 14610198
  32. Enhancement of DNA vaccine potency in rhesus macaques by electroporation.
    Vaccine. 2004 Jun 23;22(19):2489-93 PMID: 15193413
  33. Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial.
    J Exp Med. 2004 Jun 21;199(12):1709-18 PMID: 15210746
  34. Expression kinetics of the interleukin-2/immunoglobulin (IL-2/Ig) plasmid cytokine adjuvant.
    Vaccine. 2004 Aug 13;22(23-24):3092-7 PMID: 15297060
  35. Human adult T-cell leukemia virus: complete nucleotide sequence of the provirus genome integrated in leukemia cell DNA.
    Proc Natl Acad Sci U S A. 1983 Jun;80(12):3618-22 PMID: 6304725
  36. SR alpha promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat.
    Mol Cell Biol. 1988 Jan;8(1):466-72 PMID: 2827008
  37. Direct gene transfer into mouse muscle in vivo.
    Science. 1990 Mar 23;247(4949 Pt 1):1465-8 PMID: 1690918
  38. Genetic immunization is a simple method for eliciting an immune response.
    Nature. 1992 Mar 12;356(6365):152-4 PMID: 1545867
  39. Heterologous protection against influenza by injection of DNA encoding a viral protein.
    Science. 1993 Mar 19;259(5102):1745-9 PMID: 8456302
  40. Molecular mechanisms of human T-cell leukemia/lymphotropic virus type I infection.
    Blood. 1995 Nov 15;86(10):3619-39 PMID: 7579327
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
Published
2005-07-00
Pages
8828-34
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC1168733
Subset
IM
Grants
NIAID NIH HHS · R01 AI058727 · United States
NIAID NIH HHS · AI-58727 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com